Advanced Analytics. Intelligent Insights.

Your medical imaging partner, we support biopharmaceutical companies across all phases of CNS clinical research

logo-outline

New consortium will use artificial intelligence technology to conduct large-scale analysis of brain changes in Huntington’s disease

New York, NY / London, UK, September 21 2022; IXICO, uniQure, PTC Therapeutics, Inc, and CHDI Foundation have formed the Huntington’s Disease Imaging Harmonization Consortium (HD-IH) to better understand the structural brain changes that occur over the course of HD.

READ MORE

MDS 2022 Poster – An automated AI-based framework for putamen volume measurement in Multiple System Atrophy

READ MORE

How Data, Imaging & AI Are Transforming MS Clinical Research

Multiple Sclerosis (MS) is an unpredictable neurological condition which affects the brain and spinal cord, potentially causing a wide range of symptoms including problems with vision, arm or leg movements, sensation, and balance. Multiple Sclerosis (MS) is the most common autoimmune disorder of the Central Nervous System (CNS), affecting around 2.

READ MORE

IXICO Webinar-Getting Neuroimaging Right — How to Succeed in Neurodegenerative Clinical Trials

An undisputed fact is that clinical trial delays are very costly. Any strategies that accelerate start-up are key to a study’s success in achieving timelines and expected budget. However, these drivers should not challenge the ultimate key objective of obtaining high-quality data without over-burdening the sites or the participants.

READ MORE

IT Systems Engineer

READ MORE

Consultancy

We can work with you on the selection and use of medical imaging and digital biomarkers for your drug development programs, directly and as part of collaborative consortia.

Read more

Early Phase

We are experts in the definition and delivery of early phase clinical development, where rigorous patient safety runs hand-in-hand with flexibility around trial design and data analytics.



Read more

Late Phase

Our global network of over 2,000 imaging centers across 75 countries ensures large-scale trials can be set up quickly and efficiently, while our custom TrialTracker platform delivers highly reliable, regulatory compliant data.

Read more

Post-Marketing

We understand the challenges of extended longitudinal studies. We support you to monitor patient safety and drug utilization for ongoing optimization of patient pathways post-marketing.

Read more

Specialist Therapeutic Focus

IXICO is a leader in determining the most suitable patients for CNS clinical trials through brain image analysis and detecting therapy-induced changes during clinical trials.

We combine specialist neuroscience knowledge, highly curated neurological patient data and proven pipeline algorithms to accurately measure brain biomarkers. Our world-class therapeutic expertise, breakthrough technology and analytics, and operational excellence makes us the partner of choice for imaging biomarker solutions in CNS clinical trials.

The diseases we work on include:

Alzheimer's Disease (AD)

IXICO is a leading provider at the forefront of advancing Alzheimer's disease (AD) imaging biomarkers, having focused on AD clinical research since 2007. We have conducted over 40 Alzheimer's disease studies, bringing together deep therapeutic expertise, breakthrough AI analytics and operational agility to deliver extraordinary clinical insights.

Read more

Huntington's Disease (HD)

IXICO is the leading company for Huntington's disease (HD) specialist imaging. Our neuroscience expertise enables global, regulatory compliant imaging and digital biomarker analytical services for clinical development. We are a trusted imaging provider and preferred supplier for pharma and biotech, with IXICO providing advanced imaging analytics for 11 HD trials.

Read more

Parkinson's Disease (PD)

IXICO first supported a clinical study for PD in 2016 and continue to invest in our technological solutions to support clinical trials in this area. PD is the second most common neurodegenerative disease, after Alzheimer’s disease. An estimated 7 to 10 million people worldwide are living with PD.

Read more

Multiple Sclerosis (MS)

We have been involved in MS since 2015 through our Assessa PML collaboration with big pharma. Multiple Sclerosis is a condition that affects the brain and spinal cord. It is the most common autoimmune disorder of the central nervous system, affecting around 2.3 million people globally as of 2015.

Read more

Progressive Supranuclear Palsy

Progressive Supranuclear Palsy (PSP) is a Parkinsonian neurological rare condition caused by the premature loss of nerve cells in certain parts of the brain, which leads to difficulties with balance, movement, vision, speech and swallowing. IXICO has supported clinical trials in this area since 2015, providing advanced analytics for 5 clinical trials across 230 global sites.

Read more

Other Rare Neurological Diseases

IXICO specialises in data collection, optimisation, and analytics of rare neurological disorders, including but not limited to Huntington's Disease (HD), Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Spinocerebellar Ataxia (SCA).

Read more
Scanner icon 2

Imaging Biomarkers

Scanner icon 2

Imaging Biomarkers

We are at the forefront of developing and validating unique neuroimaging methods and MRI and PET image analysis techniques. This enables us to provide you with accurate, rich structural and functional information.

AI icon 2

Analytics & AI

AI icon 2

Analytics & AI

In neuroscience, AI has applications across the entire spectrum of understanding and treating disease. Our sophisticated AI technology and analytics support your clinical development programmes by interpreting complex patient data into valuable insight.

Data platforms icon 2

Data Platforms

Data platforms icon 2

Data Platforms

Our fully compliant image and digital data management provides everything you need to manage complex data workflows in CNS clinical trials. Our secure online digital platform supports your clinical decision-making, from patient selection to post-marketing surveillance.